{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:00:50Z","timestamp":1780117250899,"version":"3.54.0"},"reference-count":0,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"am","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Upadacitinib is the sole Janus kinase inhibitor approved for Crohn\u2019s disease in Japan, with its short-term efficacy already known. However, its long-term real-world outcomes remain unclear. This study aimed to evaluate its long-term continuation rates in patients with Crohn\u2019s disease and to identify predictive factors for sustained treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center retrospective study included 41 patients with Crohn\u2019s disease treated with upadacitinib between July 2023 and April 2025. Continuation rates at 1 and 2 years defined the primary outcomes. Furthermore, predictive factors for treatment discontinuation, predictive scoring system development, upadacitinib\u2019s effects on perianal draining fistulas, endoscopic outcomes, and adverse events were the secondary outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cumulative continuation rates were 67% and 63% at 1 and 2 years, respectively. In univariate analysis, factors such as age \u2265 40 years, penetrating disease behavior, prior intestinal resection, small-bowel stoma, prior exposure to\u2009\u2265\u20093 biologics, low baseline inflammation (C-reactive protein &amp;lt; 0.34\u2009mg\/dL and Simple Endoscopic Score for Crohn\u2019s Disease &amp;lt; 8), week 4 hemoglobin &amp;lt; 11.4\u2009g\/dL, week 4 albumin &amp;lt; 4.1\u2009g\/dL, and 5-aminosalicylic acid nonuse were associated with upadacitinib discontinuation. A predictive scoring system (0\u20138 points) demonstrated that patients with scores &amp;lt;3 had significantly better continuation rates than those with scores \u22653 (median: 703 vs. 341 days). Within 24 weeks of upadacitinib use, 2 of 5 patients developed perianal fistula closure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In Crohn\u2019s disease, upadacitinib continuation rates can be predicted using baseline patient characteristics and early biomarkers at week 4.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/crocol\/otag047","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T11:40:37Z","timestamp":1779968437000},"source":"Crossref","is-referenced-by-count":0,"title":["Long-term Treatment Outcomes of Upadacitinib for Crohn's Disease: A Single-center Retrospective Study"],"prefix":"10.1093","author":[{"given":"Takahiro","family":"Ito","sequence":"first","affiliation":[{"name":"Sapporo Higashi Tokushukai Hospital Inflammatory Bowel Disease Center, , Sapporo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Matsunaga","sequence":"additional","affiliation":[{"name":"Sapporo Higashi Tokushukai Hospital Inflammatory Bowel Disease Center, , Sapporo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Ohno","sequence":"additional","affiliation":[{"name":"Sapporo Higashi Tokushukai Hospital Inflammatory Bowel Disease Center, , Sapporo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muchir","family":"Shi","sequence":"additional","affiliation":[{"name":"Sapporo Higashi Tokushukai Hospital Inflammatory Bowel Disease Center, , Sapporo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuo","family":"Maemoto","sequence":"additional","affiliation":[{"name":"Sapporo Higashi Tokushukai Hospital Inflammatory Bowel Disease Center, , Sapporo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,29]]},"container-title":["Crohn's &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otag047\/68434512\/otag047.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otag047\/68434512\/otag047.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T04:04:18Z","timestamp":1780113858000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article\/doi\/10.1093\/crocol\/otag047\/8698325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1093\/crocol\/otag047","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"otag047"}}